Profil
Dr. Andrew Baker is Partner at GBS Venture Partners Pty Ltd., Non-Executive Director at Verva Pharmaceuticals Ltd., and Non-Executive Director at Xenome Ltd.
He is on the Board of Directors at Hatchtech Pty Ltd, Spinifex Pty Ltd, Verva Ltd, and Xenome Ltd.
Dr. Baker was previously employed as Deputy Director by Johnson & Johnson Research Pty Ltd., a Principal by Genentech, Inc., and a Principal by Bayer Corp.
He received his undergraduate degree from the University of Sydney and a doctorate degree from Australian National University.
Anciens postes connus de Andrew Baker
| Sociétés | Poste | Fin |
|---|---|---|
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Directeur/Membre du Conseil | 01/01/2012 |
Cryptopharma Pty Ltd.
 Cryptopharma Pty Ltd. Medical SpecialtiesHealth Technology Cryptopharma Pty Ltd. develops novel anti-inflammatory therapeutic agents for the treatment of pulmonary diseases. It focuses on the development of CP92, a treatment of Cystic Fibrosis. The company was founded by Alastair George Stewart and John Lambert in October 2000 and is headquartered in Victoria, Australia. | Président | 14/09/2009 |
Euthymics Bioscience, Inc.
 Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Hatchtech Pty Ltd.
 Hatchtech Pty Ltd. Pharmaceuticals: MajorHealth Technology Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia. | Directeur/Membre du Conseil | - |
GBS Venture Partners Pty Ltd.
 GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne. | Corporate Officer/Principal | - |
Formation de Andrew Baker
| The University of Sydney | Undergraduate Degree |
| Australian National University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Cryptopharma Pty Ltd.
Cryptopharma Pty Ltd. Medical SpecialtiesHealth Technology Cryptopharma Pty Ltd. develops novel anti-inflammatory therapeutic agents for the treatment of pulmonary diseases. It focuses on the development of CP92, a treatment of Cystic Fibrosis. The company was founded by Alastair George Stewart and John Lambert in October 2000 and is headquartered in Victoria, Australia. | Health Technology |
Verva Pharmaceuticals Ltd.
 Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Health Technology |
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
| Johnson & Johnson Research Pty Ltd. | |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
GBS Venture Partners Pty Ltd.
GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne. | Finance |
Hatchtech Pty Ltd.
Hatchtech Pty Ltd. Pharmaceuticals: MajorHealth Technology Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia. | Health Technology |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Commercial Services |